136. Vaccine economics, and why we need trade to end the pandemic

Episode Summary

Executive Summary: This episode examines how COVID-19 vaccines should be financed, manufactured, and distributed fairly in a world where supply will initially be scarce. The hosts and Ngozi Okonjo-Iweala argue that Gavi, CEPI, and the COVAX facility can pool demand and risk to improve access, but vaccine nationalism, export restrictions, and political incentives could undermine cooperation and leave poorer countries behind.

Main Topics: Vaccine scarcity and global allocation (Priority: 5/5): The episode frames COVID-19 vaccines as the world's hottest commodity and asks how to distribute a limited supply fairly once one is developed. Gavi's role in correcting market failure (Priority: 5/5): Ngozi Okonjo-Iweala explains that Gavi was created to solve unequal vaccine access by combining governments, donors, multilaterals, pharma, and civil society. Manufacturing, patents, and trade constraints (Priority: 4/5): The discussion highlights that vaccine production is highly specialized, limited to certified manufacturers, and not easily substituted through local compulsory licensing. COVAX and the Advanced Market Commitment (Priority: 5/5): COVAX is presented as a mechanism to pool demand, guarantee prices and volumes, and support access for 92 low- and lower-middle-income countries. CEPI's portfolio-based supply strategy (Priority: 4/5): CEPI reduces risk by funding multiple vaccine candidates and securing commitments to share successful vaccines, rather than betting on a single candidate. Vaccine nationalism and export restrictions (Priority: 5/5): The hosts argue that rich countries may hoard doses or block exports, making cooperative schemes vulnerable to mistrust and geopolitical retaliation. WTO reform and pandemic governance (Priority: 3/5): Okonjo-Iweala argues the WTO should update trade, IP, and licensing rules so it can help govern life-saving commodities during pandemics.

Key Arguments: Vaccine access has historically been unequal, so institutions like Gavi are necessary to prevent poor countries from being left behind. Pooling demand through COVAX can create a large guaranteed market, encouraging manufacturers to produce enough doses faster and at better prices. Vaccines are harder to manufacture than many medicines because production requires certification, specialized facilities, and complex supply chains. Compulsory licensing is less useful for vaccines than for other drugs because many developing countries lack certified local manufacturers. CEPI's portfolio strategy spreads scientific risk across multiple candidates, improving the odds that at least one vaccine succeeds. Rich countries may refuse to share vaccines if they fear domestic backlash or if they distrust others not to impose export restrictions. Past crises, including PPE shortages and earlier outbreaks, show that governments often prioritize domestic supply over international sharing. Even wealthy countries have incentives to cooperate because supply-chain retaliation could disrupt key inputs like adjuvants. The WTO should use the pandemic to strengthen rules around trade, intellectual property, and licensing for essential medical goods.

Data Points: Vaccines in development: 165 - Number of COVID-19 vaccine candidates in development at the beginning of August Vaccines in clinical trials: 26 - Subset of candidates already in clinical trials Vaccines in phase three trials: 6 - Candidates in the final testing phase before distribution could begin Children vaccinated by Gavi: 760 million - Gavi's total vaccination reach since its creation Lives saved by Gavi: 30 million - Estimated lives saved through Gavi-supported vaccination Gavi 2021-2025 goal: 300 million children - Target for vaccination over the next five years Gavi 2021-2025 lives saved goal: 8 million - Projected lives saved under the next five-year target Example vaccine prices in rich vs. supported markets: $100 down to $25, $3.50, or $2.50 - Illustrates how Gavi helps lower vaccine costs for poorer countries Developing countries in COVAX need support: 92 countries - Low- and lower-middle-income countries eligible for assistance through COVAX Global vaccine production capacity by end of 2021: 2 to 4 billion doses - Estimate from CEPI cited in the episode World population: Around 8 billion people - Used to show global vaccine supply will be insufficient at first Initial coverage target: About 20% of each participating country's population - COVAX's planned allocation level, enough for health workers and vulnerable groups Episode date reference: Early August 2020 - Timeframe used for development, procurement, and sign-up discussions

Pivotal Quotes: "GAVI started in a sense as a response to a market failure" — Ngozi Okonjo-Iweala: Explaining why the organization was founded to improve vaccine access in developing countries "This is actually a time for the WTO to shine." — Ngozi Okonjo-Iweala: Her view on the WTO's role in updating trade and IP rules during the pandemic "The tragedy of vaccine nationalism? Only cooperation can end the pandemic." — Samair Caines / referenced essay title: Summing up the episode's central normative argument about global cooperation

Implications: The episode argues that equitable vaccine access depends on international cooperation, not just scientific success. If countries hoard doses or block exports, poorer nations will be left behind and supply chains may retaliate, prolonging the pandemic for everyone.